These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33090917)

  • 41. Correlation Between Testosterone and PSA Kinetics in Metastatic Prostate Cancer Patients Treated With Diverse Chemical Castrations.
    Reis LO; Denardi F; Faria EF; Silva ED
    Am J Mens Health; 2015 Sep; 9(5):430-4. PubMed ID: 25294865
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?
    Pickles T; Hamm J; Morris WJ; Schreiber WE; Tyldesley S
    BJU Int; 2012 Dec; 110(11 Pt B):E500-7. PubMed ID: 22564197
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prostate cancer and androgen deprivation: optimal castration? Prospects and developments.
    Boccafoschi C
    Arch Ital Urol Androl; 2011 Mar; 83(1):63-6. PubMed ID: 21585175
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Subcutaneous in situ gel delivered leuprolide acetate's consistent and prolonged drug delivery maintains effective testosterone suppression independent of age and weight in men with prostate cancer.
    Renzulli JF; Tagawa ST; Atkinson SN; Boldt-Houle DM; Moul JW
    BJUI Compass; 2020 May; 1(2):64-73. PubMed ID: 35474709
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Testosterone Reduction of ≥ 480 ng/dL Predicts Favorable Prognosis of Japanese Men With Advanced Prostate Cancer Treated With Androgen-Deprivation Therapy.
    Yamamoto S; Sakamoto S; Minhui X; Tamura T; Otsuka K; Sato K; Maimaiti M; Kamada S; Takei A; Fuse M; Kawamura K; Imamoto T; Komiya A; Akakura K; Ichikawa T
    Clin Genitourin Cancer; 2017 Dec; 15(6):e1107-e1115. PubMed ID: 28882738
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer.
    de la Rosette J; Davis R; Frankel D; Kold Olesen T
    Int J Clin Pract; 2011 May; 65(5):559-66. PubMed ID: 21342376
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combination treatment versus LHRH alone in advanced prostatic cancer.
    Ferrari P; Castagnetti G; Ferrari G; Baisi B; Dotti A
    Urol Int; 1996; 56 Suppl 1():13-7. PubMed ID: 8776812
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: a phase I assessment.
    Oefelein MG
    Urology; 1999 Oct; 54(4):694-9. PubMed ID: 10510930
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer.
    Heyns CF; Simonin MP; Grosgurin P; Schall R; Porchet HC;
    BJU Int; 2003 Aug; 92(3):226-31. PubMed ID: 12887472
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy.
    Nejat RJ; Rashid HH; Bagiella E; Katz AE; Benson MC
    J Urol; 2000 Dec; 164(6):1891-4. PubMed ID: 11061874
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprolerin and triptolerin in patients with metastatic prostate cancer].
    Abbou CC; Lucas C; Leblanc V
    Prog Urol; 1997 Dec; 7(6):984-95. PubMed ID: 9490144
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy over time of LHRH analogs in the treatment of PCa--a prospective analysis using serum testosterone to determine dosing intervals.
    Greil S; Robinson EA; Singal B; Kleer E
    Urology; 2009 Mar; 73(3):631-4. PubMed ID: 19110301
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement.
    Bogdanos J; Karamanolakis D; Milathianakis C; Repousis P; Tsintavis A; Koutsilieris M
    Anticancer Res; 2003; 23(2C):1757-62. PubMed ID: 12820454
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nadir Testosterone after Long-Term Followup Predicts Prognosis in Patients with Prostate Cancer Treated with Combined Androgen Blockade.
    Kamada S; Sakamoto S; Ando K; Muroi A; Fuse M; Kawamura K; Imamoto T; Suzuki H; Nagata M; Nihei N; Akakura K; Ichikawa T
    J Urol; 2015 Nov; 194(5):1264-70. PubMed ID: 25861958
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pre-treatment testosterone levels: significance in androgen deprivation therapy.
    Hickey D; Todd B; Soloway MS
    J Urol; 1986 Nov; 136(5):1038-40. PubMed ID: 3095566
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intermittent androgen suppression--ready for prime time?
    Ischia J; Goldenberg SL
    J Urol; 2012 Jun; 187(6):1956-7. PubMed ID: 22503023
    [No Abstract]   [Full Text] [Related]  

  • 58. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
    Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer.
    Perez-Marrero R; Tyler RC
    Expert Opin Pharmacother; 2004 Feb; 5(2):447-57. PubMed ID: 14996640
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation.
    Tunn UW; Gruca D; Bacher P
    Clin Interv Aging; 2013; 8():457-64. PubMed ID: 23637525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.